Ownership history in EntryPoint Capital, LLC Β· 6 quarters on record
This page tracks every 13F SEC filing in which EntryPoint Capital, LLC reported a position in IRONWOOD PHARMACEUTICALS INC (IRWD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π EntryPoint Capital, LLC underperformed the S&P 500 by β14.3% annually on this IRWD position. Timing score: 50% (2/4 decisions correct). Average cost basis: $2.48. Maximum drawdown during holding period: β83.1%.
β Significantly underperformed the S&P 500 by 14.3% ann.
4 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
2 of 4 add/trim decisions correct
Best entry: $1.47 (2025 Q1) Β· Worst: $8.71 (2024 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 1 trim. Bought during 2 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.09% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size